Tianjin Pharmaceutical Da Ren Tang (SGX:T14) estimated a net profit attributable to equity holders for the first six months of the year to range between 1.84 billion yuan to 2.0 billion yuan, according to a filing with the Singapore Exchange on Monday.
The increase will represent a 180% to 204% year over year.
The company has attributed this to the disposal of its remaining stake in Tianjin TSKF Pharmaceutical to Haleon China and Haleon CH SARL for around 1.54 billion yuan.
Shares of the company were up nearly 1% in recent trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.